Study finds prostate cancer treatment can wait for most men & Pfizer buys Seagen, maker of targeted cancer drugs

A study of prostate cancer patients compared three approaches: watchful waiting, surgery, and radiation

March 14, 2023 Check out STAT+

Sponsored By

Dr. Edwin P. Ewing, Jr./CDC via AP Prostate cancer treatment can wait for most men, study finds The results are encouraging for men who want to avoid treatment-related sexual and incontinence issues, said one prostate cancer specialist. By Carla K. Johnson — Associated Press STAT+ | Pfizer buys Seagen, maker of targeted cancer drugs, for $43 billion The Seagan deal helps Pfizer, in need of new sources of revenue, by adding a lineup of cancer drugs called antibody-drug conjugates. By Adam Feuerstein 'This is a nonpartisan issue': Planned Parenthood's Alexis McGill Johnson on fighting for reproductive rights Planned Parenthood and its CEO Alexis McGill Johnson are dealing with an ever-shifting landscape of legal restrictions on reproductive care. By Eric Boodman Neilson Barnard/Getty Images for New York Times STAT+ | Illumina has been ignoring its investors, but it can't ignore Carl Icahn Icahn argues Illumina is playing a losing hand with its actions related to the pursuit of its merger with Grail. By Matthew Herper

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser